Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CDIO 
Cardio Diagnostics Holdings Inc (CDIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: CDIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $60
1 Year Target Price $60
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 3.47% | Avg. Invested days 64 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.86M USD | Price to earnings Ratio - | 1Y Target Price 60 |
Price to earnings Ratio - | 1Y Target Price 60 | ||
Volume (30-day avg) 1 | Beta 2.89 | 52 Weeks Range 3.22 - 53.10 | Updated Date 09/17/2025 |
52 Weeks Range 3.22 - 53.10 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.75 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -22457.51% |
Management Effectiveness
Return on Assets (TTM) -54.15% | Return on Equity (TTM) -97.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -565022 | Price to Sales(TTM) 351.41 |
Enterprise Value -565022 | Price to Sales(TTM) 351.41 | ||
Enterprise Value to Revenue 158.51 | Enterprise Value to EBITDA -22.48 | Shares Outstanding 1763130 | Shares Floating 1630542 |
Shares Outstanding 1763130 | Shares Floating 1630542 | ||
Percent Insiders 7.16 | Percent Institutions 4.81 |
Upturn AI SWOT
Cardio Diagnostics Holdings Inc
Company Overview
History and Background
Cardio Diagnostics Holdings Inc. is focused on pioneering precision medicine through non-invasive cardiovascular tests. Founded with the aim of transforming cardiovascular disease diagnostics, the company leverages artificial intelligence and machine learning to improve early detection and patient care.
Core Business Areas
- AI-Driven Diagnostics: Develops and commercializes AI-driven tests for early detection of cardiovascular diseases.
- Clinical Services: Offers clinical services including risk assessments and patient management solutions.
Leadership and Structure
The leadership team is composed of experienced executives in diagnostics, healthcare, and technology. The organizational structure is designed to support innovation, commercialization, and strategic partnerships.
Top Products and Market Share
Key Offerings
- AORTAplex: AORTAplex is a blood test designed to evaluate an individual's risk of developing an abdominal aortic aneurysm (AAA). Competitors include standard ultrasound imaging and other predictive biomarker tests for cardiovascular risk assessment. Market share data is not publicly available, and revenue figures are not disclosed in sufficient detail.
- Corus CAD: Corus CAD is a diagnostic blood test used to aid physicians in evaluating patients with signs and symptoms suggestive of obstructive coronary artery disease (CAD). Competitors include MyoSeq by Predictive Health Diagnostics (PHD), HeartCheck by Vascular Health Diagnostics (VHD), and direct competitors like GE Healthcare (GE), Siemens Healthineers (SIEGY), and Philips Healthcare (PHG). Market share data is not publicly available, and revenue figures are not disclosed in sufficient detail.
Market Dynamics
Industry Overview
The cardiovascular diagnostics market is driven by an aging population, increasing prevalence of cardiovascular diseases, and advancements in diagnostic technologies. The market is competitive, with established players and emerging companies focusing on innovative solutions.
Positioning
Cardio Diagnostics Holdings Inc. aims to differentiate itself through AI-powered diagnostics, focusing on early detection and personalized risk assessment. Its competitive advantage lies in its proprietary technology platform and expertise in cardiovascular biomarkers.
Total Addressable Market (TAM)
The global cardiovascular diagnostics market is expected to reach billions of dollars. Cardio Diagnostics is positioned to capture a segment of this market by providing novel diagnostic solutions focused on early detection and preventative care.
Upturn SWOT Analysis
Strengths
- AI-driven diagnostic platform
- Focus on early disease detection
- Experienced leadership team
- Proprietary technology
Weaknesses
- Limited commercialization track record
- Reliance on funding for growth
- Small market capitalization
- Limited Brand Recognition
Opportunities
- Expanding into new cardiovascular disease areas
- Strategic partnerships with healthcare providers
- Increasing adoption of AI in healthcare
- Growing demand for personalized medicine
Threats
- Competition from established diagnostic companies
- Regulatory hurdles
- Reimbursement challenges
- Technological obsolescence
Competitors and Market Share
Key Competitors
- GE (GE)
- Siemens Healthineers (SIEGY)
- Philips Healthcare (PHG)
- MyoSeq (PHD)
- HeartCheck (VHD)
Competitive Landscape
Cardio Diagnostics Holdings Inc. faces competition from established diagnostic companies with greater resources and market share. Its advantages lie in its AI-driven technology and focus on early detection. However, it needs to overcome challenges related to commercialization and market adoption.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are not readily available in a structured format.
Future Projections: Future growth projections are not readily available in a structured format.
Recent Initiatives: Recent initiatives include expanding the product pipeline and establishing partnerships with research institutions and healthcare providers.
Summary
Cardio Diagnostics Holdings Inc. is a growing company with innovative AI-driven diagnostic technology poised to capture a segment of the cardiovascular diagnostics market. However, it is a small market share player. It faces challenges related to commercialization, competition from larger companies, and regulatory hurdles. Strategic partnerships and successful market adoption are crucial for its long-term success. Continued innovation and expanding product pipelines are also very important to focus on.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Market share data are estimates based on available information and may not be precise. Financial data may be limited due to company size and reporting requirements.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cardio Diagnostics Holdings Inc
Exchange NASDAQ | Headquaters Chicago, IL, United States | ||
IPO Launch date 2022-01-14 | Co-Founder, CEO & Director Dr. Meeshanthini V. Dogan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://cdio.ai |
Full time employees 13 | Website https://cdio.ai | ||
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, including concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.